Developing better adjuvants for HIV vaccines
Official title: Rational Systemic Characterization and Selection of Adjuvants for HIV Vaccine Candidates (R-CASA)
Funded at Scripps Research Institute, the · NIH-11161215 · Data updated 2026-11-12
This study is working on finding the best mixes of ingredients for an HIV vaccine to make it more effective, so that people can have better protection against the virus in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,990,835 |
| NIH project number | 75N93024C00053-0-9999-1 |
| Project ID | NIH-11161215 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of HIV infection who may benefit from improved vaccine options.
✕Less likely to help
Patients who are already living with HIV and are seeking treatment rather than prevention may not benefit from this research.
What this research studies
This research focuses on improving HIV vaccine development by identifying the best combinations of immunogens and adjuvants. The project will create standardized protocols and assays to systematically evaluate these combinations before they enter clinical trials. By screening various formulations, the research aims to enhance the effectiveness of future HIV vaccines, ultimately leading to better protection against the virus.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV vaccines that provide better immunity against the virus.
How similar studies have gone: Previous research has shown promise in developing effective adjuvants for vaccines, suggesting that this approach could yield significant advancements in HIV vaccine efficacy.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Chatterjee, Arnab Kumar — Scripps Research Institute, the
- Study coordinator: Chatterjee, Arnab Kumar
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.